Living Longer with HER2+ Metastatic Breast Cancer

September 25, 2021
Breast cancer is the second most common cancer among women in the United States. The American Cancer Society's estimated that 281,550 new cases of invasive breast cancer will be diagnosed in American women in 2021. In addition, some 49,290 new cases of ductal carcinoma in situ (DCIS) will be diagnosed and approximately 43,600 women will die from breast cancer. Advances in our knowledge of breast cancer pathophysiology and its clinical implications have led to the development of new therapies and opportunities to tailor chemotherapy based on tumor biology and/or tumor burden. New and emerging therapies for breast cancer include cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, programmed death receptor-1 (PD-1) /PD-1 inhibitors, poly ADPribose polymerase (PARP) inhibitors, monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and vaccines that stimulate immune response targeting tumor-associated antigens. New Drug approvals in recent years include the PI3Kα-specific inhibitor alpelisib, ado-trastuzumab emtansine, fam-trastuzumab-deruxtecan-nxki, combination therapy with atezolizumab and nab-paclitaxel, tucatinib, margetuximab (anti-HER2 mAb), and sacituzumab govitecan-hziy for metastatic triple-negative breast cancer. Understanding the optimal use of these novel therapies based on the breast cancer diagnosis is critical for individualizing patient therapy and improving outcomes.

Target Audience

Medical, surgical, and radiation oncologists as well as primary care physicians, gynecologists, medical professionals, nurse practitioners, physicians’ assistants, nurses, and health care professionals with an interest in HER2+ metastatic breast cancer are invited to attend.

Learning Objectives

After completing this activity, participants will be able to:

  • Review the clinical trial data on treatment pathways and associated new/ emerging therapies that improve overall survival for patients with HER2+ metastatic breast cancer;
  • Discuss strategies for managing/preventing treatment-related adverse events (TRAEs) in patients with HER2+ metastatic breast cancer;
  • Identify best practices for individualizing treatment plans based on patient factors in HER2+ metastatic breast cancer.
Additional information
ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
Professionalism
For more information, please contact:
CME Coordinator Contact Name: 
myMedEd
CME Coordinator Contact Email: 
Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Event starts: 
09/25/2021 - 12:15pm
Event ends: 
09/25/2021 - 1:15pm
Activity opens: 
09/25/2021
Activity expires: 
12/25/2021
Virtual Conference
WANT TO KNOW MORE?
Click here to learn more about the 3rd Annual Breast Cancer Symposium!
 
Questions?
Contact myMedEd via e-mail here.
 
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office at BCS@mymededco.com.


The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.

FACULTY
  Chau T. Dang, MD
  Medical Director
  MSK Westchester Medical Oncology
  Attending, Breast Medicine Service
  Memorial Sloan Kettering Cancer Center
  New York, NY
 
  Neil Iyengar, MD
  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  Associate Attending, Rockefeller University
  Assistant Professor of Medicine
  Weill Cornell Medicine
                          New York, NY
 
  Shanu Modi, MD
  Associate Member
  Section Head HER2 Breast Program
  Memorial Sloan Kettering Cancer Center
  Associate Professor, Weill Cornell Medical College
  New York, NY


Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and New York Oncology Hematology, PC, and in collaboration with my myMedEd, Inc. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University Of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Other Healthcare Professions Credit
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
REGISTRATION: Complete conference information and registration can be accessed by clicking below!
 
Please login or create an account to proceed.